A study evaluating safety of Tocilizumab, IL-1 inhibitors Anakinra & Canakinumab and Etanercept in patients with Juvenile Idiopathic Arthritis
Latest Information Update: 18 Jun 2019
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- 15 Jun 2019 Results (n=48) assessing safety of canakinumab in pediatric patients, presented at the 20th Annual Congress of the European League Against Rheumatism.
- 16 Jun 2018 Results of a cohort of patients who started first-line anakinara (n=47) presented at the 19th Annual Congress of the European League Against Rheumatism.
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism